The presented PBPK model of fluvoxamine has been developed to be used in a PBPK Drug-Drug-Interactions (DDI) network with fluvoxamine as an inhibitor of CYP2C19 and CYP1A2. This version has not been qualified for the use as CYP3A4 inhibitor.
This release contains:
- the PK-Sim snapshot (*.json) file of the PBPK model (what is a "PK-Sim snapshot")
- static content (e.g. text blocks, *.md files) as inputs for an evaluation plan
- the evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model
- evaluation report
Downloads
Fluvoxamine PK-Sim snapshot file
Fluvoxamine evaluation report
Fixed issues and Improvements
- Removed unused data set
- Update evaluation plan schema
- Updated titlepage to use generic versioning
- Generic versioning
- Add pk-sim project and evaluation report
- Update README.md
- All references lower case
- Typos
- Added spellcheck
- Broken Link fixes
- Remove source meta data from observed data